Seneca Growth Capital VCT plc (SVCT) · LSE:SVCT
Seneca Growth Capital VCT plc (SVCT) — Seneca Growth Capital VCT — Investor Presentation (May 2026)
24 slides from Seneca Growth Capital VCT plc (SVCT)'s investor presentation, May 2026
Slide 1: Investor Update Presentation
Investor Update Presentation May 2026
Slide 2: Important Notice
Seneca Growth Capital VCT Important Notice The following presentation, including a hard copy of these slides/the talks given by the presenters, the information with access to any additional information or to update the Presentation or to correct any inaccuracies in, or communicated during any delive
Slide 3: Welcome from the Team
Seneca Growth Capital VCT Welcome from the Team The VCT Board of Directors Presenting from Presenting from the VCT Board of Directors the Investment Manager Ian Dighé Independent non-executive Director and Chair of the Board Mary Anne Cordeiro Senior Independent non-executive Director Richard Manley
Slide 4: Company Overview
Seneca Growth Capital VCT Company Overview Seneca Growth Capital VCT Ordinary Two share classes B Share Pool Share Pool Legacy Share Class Active Share Class • Continuing to realise investments • 19 Portfolio Companies and maximise value • £10.2m NAV • 2 key AIM quoted portfolio companies • £3.3m in
Slide 5: FY 2025 Activity
Seneca Growth Capital VCT FY 2025 Activity B Share Pool Funds Raised Deployed Exited £708k £400k £400k July 2025 Sep 2025 Verici DX Forma-Care Full Exit Partial Exit £200k £200k c.£0.2m proceeds £0.1m proceeds Follow-on Follow-on Overall return 1.1x Return of 1.5x • Rationalisation of 7 sub-scale AI
Slide 6: FY 2025 Activity: Ordinary Share Pool
Seneca Growth Capital VCT FY 2025 Activity Ordinary Share Pool Exited Dividends £500k £650k Partial Exit of Scancell 8.0p Ordinary share dividends paid during the year Holdings Plc at a 1.7x • 3.0p June 2025 return on original • 5.0p November 2025 investment cost 81.3p Cumulative Ordinary share divi
Slide 7: Q1 2026 Activity
Seneca Growth Capital VCT Q1 2026 Activity B Share Pool Ordinary Share Pool SkinBioTherapeutics sold post year-end: • Ordinary Share NAV as at 31 March 2026 (unaudited): 8.6p per Ordinary share (+0.7p) • 1,272,107 shares realised for £244k • 2.5x blended overall return on original Movement in Scance
Slide 8: B Share Pool Overview as at 31 December 2025
Seneca Growth Capital VCT B Share Pool Overview as at 31 December 2025 Total NAV Breakdown 19 Investee Companies by Sector £10.2m £7.0m total NAV invested Software £2.1m 30% Health & Consumer £0.4m 6% Private companies £4.9m 48% Pharma / Biopharma £1.6m 23% Manufacturing £0.4m 6% Cash £3.3m 32% Busi
Slide 9: B Share Pool NAV Performance
Seneca Growth Capital VCT B Share Pool NAV Performance NAV per B Share: Change from 1/1/25 to 31/3/26 60.0p 55.0p 51.8p (0.2)p 50.0p (1.0)p 0.7p NAV per Share in Pence 45.0p (5.9)p (1.4)p 41.0p (3.0)p 0.2p 0.1p 39.7p 40.0p (1.3)p (0.3)p 35.0p 30.0p 25.0p 20.0p 9
Slide 10: B Share Pool – Private Company Valuation Movements
Seneca Growth Capital VCT B Share Pool – Private Company Valuation Movements 2025 Carrying Value Contribution to Movement in year Movement in year Private Company Portfolio 31/12/2025 NAV Movement (£000) (%) (£000) (p) Convenient Collect Ltd t/a 1,380 428 45% 1.7 HubBox SolasCure Ltd 1,133 - - - Fab
Slide 11: B Share Pool – Private Company Valuation Movements
Seneca Growth Capital VCT B Share Pool – Private Company Valuation Movements Company (Dec 2025; Value: (£3,134k) Key Developments in 2025 HubBox (£1,380k) • Completed a £5.8m funding round led by Puma VCTs at a £27m pre-money valuation, materially strengthening the balance sheet and operational runw
Slide 12: B Share Pool – Private Company Valuation Movements
B Share Pool – Private Company Valuation Movements Company (Dec 2025; Value: (£712k) Key Developments in 2025 • Completed a restructuring programme, delivering c.£1m+ of annualised savings, with cash balances remaining robust at Bright Network (£712k) c.£3m+. ▼ -£0.5m (-2.1p NAV impact) • Core UK pl
Slide 13: The B Share Pool Quoted Company Updates
Seneca Growth Capital VCT The B Share Pool Quoted Company Updates 13
Slide 14: AIM/AQSE Movement in NAV
Seneca Growth Capital VCT B Share Pool AIM/AQSE Movement in NAV 2025 Carrying Value Share Price Contribution to Movement in year AIM Company Portfolio 31/12/25 Movement in year NAV Movement (£000) (£000) (%) (p) Aptamer Group plc 505 328 185% 1.3 ProBiotix Health plc 242 37 18% 0.2 Arecor Therapeuti
Slide 15: Aptamer Group PLC +185%, +£328k in 2025
Aptamer Group PLC +185%, +£328k in 2025 Seneca Growth Capital VCT Investment Summary: Value as at 31 Dec 25: £505k Contribution to NAV movement to 31 Dec 25: +£328k, +1.32p (+3%) Value as at 31 Mar 26 (unaudited): £303k Performance Summary: Share price responded to sustained commercial traction, par
Slide 16: Poolbeg Pharma Plc -44%, £(234)k in 2025
Seneca Growth Capital VCT Poolbeg Pharma Plc -44%, £(234)k in 2025 Investment Summary: Value as at 31 Dec 25: £294k Contribution to NAV movement to 31 Dec 25: -£234k, - 0.94p (-2%) Value as at 31 Mar 26 (unaudited): £325k Performance Summary: Poolbeg's share price responds sharply to positive newsfl
Slide 17: Verici Dx Plc -80%, £(6)k in 2025
Verici Dx Plc -80%, £(6)k in 2025 Seneca Growth Capital VCT Investment Summary: Value as at 31 Dec 25: £302k Contribution to NAV movement to 31 Dec 25: -£6k, - 0.03p (0%) Value as at 31 Mar 26 (unaudited): £228k Performance Summary: Verici Dx delivered strong commercial growth in FY25, with volumes
Slide 18: B Share Portfolio – Total Return
Seneca Growth Capital VCT B Share Portfolio – Total Return • Total Return of 62.0p as at 31 December 2025 (60.7p as at 31 March 2026) • Annual dividends of 3p since 2019 following launch of B share class • Cumulative dividends of 21.0p paid to date; 3.0p dividends paid during FY25 (1.5p May 2025 + 1
Slide 19: Outlook
Seneca Growth Capital VCT Outlook Focus on maximizing the value of the current portfolio Seek to achieve exits to support further dividends to investors Support existing portfolio companies Continue to adopt a highly selective approach to new investments Fundraising requirements being kept under rev
Slide 20: The Ordinary Share Pool
Seneca Growth Capital VCT The Ordinary Share Pool 20
Slide 21: Ordinary Share Pool Overview
Seneca Growth Capital VCT Ordinary Share Pool Overview Net Assets as at 31 December 2025: £0.6m (7.9p per share) 31 March 2026 (unaudited): £0.7m (8.6p per share) 42% 41% AIM quoted (Scancell) 41% AIM quoted (Arecor) 17% Cash 42% 17% 21
Slide 22: Ordinary Share Pool Overview
Seneca Growth Capital VCT Ordinary Share Pool Overview Update on two key aspects of Ord Share Pool 1 2 NAV moves in line with Ord Share Pool’s Dividends two quoted investments in addition to dividends Scancell Exit We actively manage our Scancell position, seeking to capitalise Opening Closing Closi
Slide 23: Q&A
Q&A Seneca Growth Capital VCT 23
Slide 24: Investor Update Presentation
Investor Update Presentation For any enquiries please contact us on 01942 295 981 or email siobhan.pycroft@senecapartners.co.uk
Seneca Growth Capital VCT — Investor Presentation (May 2026) on 6ix